Insulin glargine and glulisine SoloSTAR^® pens for the treatment of diabetes

References

• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature414(6865), 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care29(6), 1263–1268 (2006).
   PubMed Web of Science ®Google Scholar
• Han TS, Sattar N, Lean M. ABC of obesity. Assessment of obesity and its clinical implications. BMJ (Clinical Research Ed.)333(7570), 695–698 (2006).
   PubMed Web of Science ®Google Scholar
• Wild SH, Byrne CD. ABC of obesity. Risk factors for diabetes and coronary heart disease. BMJ (Clinical Research Ed.)333(7576), 1009–1011 (2006).
   PubMedGoogle Scholar
• Barnett AH. A review of basal insulins. Diabet. Med,20(11), 873–885 (2003).
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med.329(14), 977–986 (1993).
   Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 837–853 (1998).
   Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 854–865 (1998).
   Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care29(8), 1963–1972 (2006).
   PubMed Web of Science ®Google Scholar
• Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care29(12), 2644–2649 (2006).
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. JAMA295(14), 1681–1687 (2006).
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care30(2), 263–269 (2007).
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed)321(7258), 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• IMS Health. IMS Midas™ June 2007, Quarterly insulin sales volume in units. (2007).
   Google Scholar
• Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care,28(11), 2673–2679 (2005).
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with Type 2 diabetes: the scope of the problem. Diabetes Care,28(10), 2543–2545 (2005).
   PubMed Web of Science ®Google Scholar
• Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs66(1), 31–49 (2006).
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes49(12), 2142–2148 (2000).
   PubMed Web of Science ®Google Scholar
• Stewart K. Insulin delivery devices. J. Pharm. Pract.17, 20–28 (2004).
   Google Scholar
• Wagner J, Malchoff C, Abbott G. Invasiveness as a barrier to self-monitoring of blood glucose in diabetes. Diabetes Technol. Ther.7(4), 612–619 (2005).
   PubMedGoogle Scholar
• Fear of the injection must not be an argument. Every second Type 2 diabetic patient needs insulin. MMW Fortschr. Med.144(49), 60 (2002).
   Google Scholar
• Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin. Pediatr. (Phila.)43(1), 69–74 (2004).
   PubMed Web of Science ®Google Scholar
• Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin. Ther.26(9), 1498–1505 (2004).
   PubMed Web of Science ®Google Scholar
• Bell DS, Clements RS Jr, Perentesis G, Roddam R, Wagenknecht L. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern. Med.151(11), 2265–2269 (1991).
   PubMed Web of Science ®Google Scholar
• Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res. Clin. Pract.28(3), 173–177 (1995).
   PubMed Web of Science ®Google Scholar
• Casella SJ, Mongilio MK, Plotnick LP, Hesterberg MP, Long CA. Accuracy and precision of low-dose insulin administration. Pediatrics91(6), 1155–1157 (1993).
   PubMed Web of Science ®Google Scholar
• Santiago OM, Khutoryansky NM, Bilbo CM, Lawton SA, Kristensen CM. Accuracy and precision of the NovoPen 3 insulin delivery device after mechanical and temperature stresses. Endocr. Pract.8(5), 351–355 (2002).
   PubMedGoogle Scholar
• Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with Type 1 or 2 diabetes mellitus. Clin. Ther.25(11), 2836–2848 (2003).
   PubMed Web of Science ®Google Scholar
• IMS Health. IMS Midas™ June 2006, Quarterly insulin sales volume in units. (2006).
   Google Scholar
• Aljahlan M, Lee KC, Toth E. Limited joint mobility in diabetes. Postgrad. Med.105(2), 99–101, 105–106 (1999).
   PubMed Web of Science ®Google Scholar
• Casanova JE, Casanova JS, Young MJ. Hand function in patients with diabetes mellitus. South Med. J.84(9), 1111–1113 (1991).
   PubMed Web of Science ®Google Scholar
• Aylward GW. Progressive changes in diabetics and their management. Eye19(10), 115–1118 (2005).
   PubMedGoogle Scholar
• Wong TY, Mitchell P. The eye in hypertension. Lancet369(9559), 425–435 (2007).
   PubMed Web of Science ®Google Scholar
• Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technol. Ther.7(4), 620–626 (2005).
   PubMedGoogle Scholar
• Starkman HS, Gleason RE, Rand LI, Miller DE, Soeldner JS. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann. Rheum. Dis.45(2), 130–135 (1986).
   PubMed Web of Science ®Google Scholar
• Savas S, Koroglu BK, Koyuncuoglu HR et al. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in Type 2 diabetic patients. Diabetes Res. Clin. Pract. (2006).
   PubMedGoogle Scholar
• Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin. Drug Deliv.4(2), 165–174 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz S, Vlajnic A. Validation of the SoloStar insulin pen. Presented at 7th Annual Diabetes Technology Meeting San Francisco, CA, USA, 25–27 October, 2007.
   Google Scholar
• Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with Type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin. Ther.28(10), 1712–1725 (2006).
   PubMed Web of Science ®Google Scholar
• Roberts A, Thornley S. Healthcare professional-reported usability of SoloStar in a 3-month observational survey in everyday clinical practice. In: 7th Annual Diabetes Technology Meeting. (Eds). (San Francisco, CA, USA (2007)
   Google Scholar
• Haak T, Edelman SV, Walter C, Lecointre B, Spollett GR. Comparison of the usability and patient preference for the new disposable insulin device SoloStar versus FlexPen, Lilly Disposable pen, and a prototype pen: an open-label study. Clin. Ther.29(4), 650–660 (2007).
   PubMed Web of Science ®Google Scholar
• Carter J, Beilin J, Morton A, De Luise M. Usability, participant acceptance and safety of SoloStar in an observational survey in everyday clinical practice. Presented at 7th Annual Diabetes Technology Meeting. San Francisco, CA, USA, 25–27 October, 2007.
   Google Scholar
• Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care25(1), 202–212 (2002).
   Google Scholar
• Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in Type 2 diabetes: the LANMET study. Diabetologia49(3), 442–451 (2006).
   PubMed Web of Science ®Google Scholar
• Lankisch M, Ferlinz K, Scherbaum WA. Dose of insulin glulisine (BOT+) reduces HbA1c and blood glucose values in patients with Type 2 diabetes. Diabetologia50(Suppl. 2), Abstract 0980 (2007).
   Google Scholar
• Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in Type 2 diabetes mellitus is not enough – what next? Diabetes Metab. Res. Rev.23(4), 257–264 (2007).
   Google Scholar
• Rhee MK, Slocum W, Ziemer DC et al. Patient adherence improves glycemic control. Diabetes Educ.31(2), 240–250 (2005).
   PubMed Web of Science ®Google Scholar